Visionary Holdings Launches Toronto-Based Joint Venture to Drive Global Commercialization of Innovative Stem Cell Therapy for Diabetes Remission, Targeting a $150 Billion Market Opportunity
Visionary Holdings (Nasdaq: GV) announced on October 22, 2025 a strategic cooperation with Jiangsu Yike to form Visionary Yike Stemcell Technologies, a Canada-based joint venture focused on stem cell R&D, clinical application, manufacturing and global commercialization.
GV will hold 85% and Yike 15%. The JV may be headquartered at GV's Toronto property (95–105 Moatfield Drive, ~40,000 sqm) and will explore cleanrooms, low-temperature biostorage, and production infrastructure. Initial targets include stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics with a stated focus on Type 1 and Type 2 diabetes; clinical evidence so far is described as preclinical/exploratory. Development is subject to regulatory, financing, and operational planning.
Visionary Holdings (Nasdaq: GV) ha annunciato il 22 ottobre 2025 una cooperazione strategica con Jiangsu Yike per formare Visionary Yike Stemcell Technologies, una joint venture con sede in Canada focalizzata su R&D di cellule staminali, applicazioni cliniche, produzione e commercializzazione globale.
GV detiene 85% e Yike 15%. La JV potrebbe avere sede presso la proprietà di GV a Toronto (95–105 Moatfield Drive, ~40.000 m2) e esaminerà cleanrooms, biostorage a basse temperature e infrastrutture di produzione. Obiettivi iniziali includono terapia con cellule staminali, ingegneria di cellule del sistema immunitario e diagnostica anti-invecchiamento supportata da IA, con un focus dichiarato su diabete di tipo 1 e tipo 2; l'evidenza clinica finora è descritta come preclinica/esplorativa. Lo sviluppo è soggetto a regolamentazione, finanziamento e pianificazione operativa.
Visionary Holdings (Nasdaq: GV) anunció el 22 de octubre de 2025 una cooperación estratégica con Jiangsu Yike para formar Visionary Yike Stemcell Technologies, una empresa conjunta con sede en Canadá centrada en I+D de células madre, aplicaciones clínicas, fabricación y comercialización global.
GV poseerá el 85% y Yike el 15%. La JV podría tener su sede en la propiedad de GV en Toronto (95–105 Moatfield Drive, ~40.000 m2) y explorará salas limpias, almacenamiento biológico a baja temperatura e infraestructura de producción. Los objetivos iniciales incluyen terapia con células madre, ingeniería de células inmunes y diagnósticos anti-envejecimiento apoyados por IA, con un enfoque declarado en diabetes tipo 1 y tipo 2; la evidencia clínica hasta ahora se describe como preclínica/exploratoria. El desarrollo está sujeto a regulaciones, financiamiento y planificación operativa.
Visionary Holdings(Nasdaq: GV)는 2025년 10월 22일 Jiangsu Yike와 전략적 협력을 발표하고 캐나다에 본사를 둔 합작법인 Visionary Yike Stemcell Technologies를 설립하여 줄기세포 연구개발(R&D), 임상 적용, 제조 및 글로벌 상용화를 추진합니다.
GV가 85%, Yike가 15%를 보유합니다. JV는 GV의 토론토 부지(95–105 Moatfield Drive, 약 40,000㎡)에 본부를 둘 수 있으며 클린룸, 저온 생물저장 및 생산 인프라를 모색합니다. 초기 목표로는 줄기세포 치료, 면역세포 공학, AI 지원 항노화 진단이 포함되며, 당뇨병 1형 및 2형에 명시적으로 초점을 둡니다. 지금까지의 임상 근거는 전임상/탐색으로 설명됩니다. 개발은 규제, 자금 조달 및 운영 계획의 영향을 받습니다.
Visionary Holdings (Nasdaq : GV) a annoncé le 22 octobre 2025 une coopération stratégique avec Jiangsu Yike pour former Visionary Yike Stemcell Technologies, une coentreprise basée au Canada axée sur la R&D des cellules souches, l’application clinique, la fabrication et la commercialisation mondiale.
GV détiendra 85% et Yike 15%. La JV pourrait être réunie à la propriété de GV à Toronto (95–105 Moatfield Drive, ~40 000 m²) et explorera des salles blanches, la biostockage à basse température et des infrastructures de production. Les objectifs initiaux incluent la thérapie par cellules souches, l’ingénierie des cellules immunitaires et des diagnostics anti-âge assistés par IA, avec un accent déclaré sur le diabète de type 1 et de type 2; les preuves cliniques à ce jour sont décrites comme précliniques/exploratoires. Le développement est soumis à la réglementation, au financement et à la planification opérationnelle.
Visionary Holdings (Nasdaq: GV) kündigte am 22. Oktober 2025 eine strategische Zusammenarbeit mit Jiangsu Yike an, um Visionary Yike Stemcell Technologies zu gründen, ein in Kanada ansässiges Gemeinschaftsunternehmen, das sich auf Stammzellen-Forschung und -Entwicklung, klinische Anwendung, Herstellung und weltweite Vermarktung konzentriert.
GV hält 85% und Yike 15%. Das JV könnte am GV-Standort in Toronto (95–105 Moatfield Drive, ca. 40.000 m²) ansässig sein und Reinräume, Biostorage bei niedrigen Temperaturen und Produktionsinfrastruktur erforschen. Erste Ziele umfassen Stammzelltherapie, Immunzell-Engineering und KI-gestützte Anti-Aging-Diagnostik, mit einem ausdrücklichen Fokus auf Typ-1- und Typ-2-Diabetes; klinische Evidenz bisher wird als präklinisch/erweitert beschrieben. Die Entwicklung unterliegt Regulierung, Finanzierung und operativer Planung.
أعلنت Visionary Holdings (Nasdaq: GV) في 22 أكتوبر 2025 عن تعاون استراتيجي مع Jiangsu Yike لتشكيل Visionary Yike Stemcell Technologies، مشروع مشترك مقره كندا ويركز على أبحاث وتطوير الخلايا الجذعية، التطبيق السريري، التصنيع والتسويق العالمي.
ستملك GV 85% و Yike 15%. قد يكون مقر الشركة المشتركة في ملكية GV في تورنتو (95–105 Moatfield Drive، نحو 40,000 م2) وستستكشف المختبرات النظيفة، التخزين البيولوجي منخفض الحرارة وبنية تحتية للإنتاج. تشمل الأهداف الأولية العلاج بالخلايا الجذعية، هندسة الخلايا المناعية، والتشخيصات المضادّة للشيخوخة المدعومة بالذكاء الاصطناعي مع تركيز مذكور على داء السكري من النوع 1 والنوع 2. حتى الآن تُعرَف الأدلة السريرية بأنها قبل السريرية/استكشافية. التطوير رهين التنظيم والتمويل والتخطيط التشغيلي.
Visionary Holdings（纳斯达克代码：GV） 于 2025年10月22日 宣布与江蘇宜客（Jiangsu Yike）达成战略合作，成立 Visionary Yike Stemcell Technologies，是一家总部位于加拿大的合资企业，专注于干细胞研发、临床应用、制造及全球商业化。
GV将持有 85%，Yike 持有 15%。该合资企业可能在 GV 的多伦多物业（95–105 Moatfield Drive，约 40,000 平方米）设立总部，并将探索洁净室、低温生物存储和生产基础设施。初步目标包括干细胞治疗、免疫细胞工程，以及由 AI 支持的抗衰诊断，明确聚焦 1 型和 2 型糖尿病；迄今的临床证据被描述为前临床/探索阶段。开发需遵循监管、融资和运营规划等条件。
- GV equity control of 85% in the joint venture
- Planned HQ on GV's ~40,000 sqm Toronto property
- JV aims for vertical integration across R&D, trials, manufacturing, sales
- Clinical evidence for diabetes described only as preclinical/exploratory
- Commercialization and facility development subject to regulatory approval
- Project outcomes contingent on financing and operational planning
Insights
JV creates a commercialization vehicle for Yike's stem cell platform using GV's Toronto campus and an 85/15 ownership split.
The transaction links a global commercialization network with a regenerative‑medicine platform and contemplates converting GV's 95–105 Moatfield Drive property into an integrated R&D and manufacturing campus. The parties plan to pursue stem cell therapy, immune cell engineering, and AI‑supported diagnostics and to progress Yike's technology toward clinical application after preclinical and exploratory results.
Key dependencies and risks include regulatory approvals, facility build‑out feasibility, and financing; the parties explicitly condition development on regulatory, financing, and operational planning. Monitor progress against three concrete milestones over the next 12–36 months: site feasibility and cleanroom planning at the Toronto property, formal initiation of clinical trials for the diabetes indication, and establishment of GMP manufacturing capability. The announcement frames a large
Under the agreement, GV and Yike will leverage their respective strengths in global commercialization and regenerative medicine with the goal of advancing the development of stem cell manufacturing and R&D hub in
The joint venture will initially focus on stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics and intervention models, leveraging Yike's proprietary platform and GV's global market infrastructure. Both parties will contribute resources and share potential benefits in proportion to their equity stakes, with GV holding
Through this collaboration, the parties plan to create a vertically integrated regenerative medicine enterprise encompassing R&D, trials, manufacturing, and global sales, which could enhance GV's long-term positioning in the North American stem cell sector.
Xiyong Hou, CEO of Visionary Holdings, commented:
"The establishment of Visionary Yike Stemcell Technologies marks a transformative milestone for GV's global health strategy. This new company is expected to be located at GV's
By combining Yike's proprietary stem cell and anti-aging technologies with GV's international commercialization network, we aim to deliver innovative, science-based solutions that aim to improve human health and longevity. This collaboration reflects our continued commitment to global innovation and value creation for shareholders."
Building on the global license agreement for Yike's stem cell technology announced earlier this month, this new joint venture is expected to serve as the operational and commercialization platform for that breakthrough technology — representing a future step in GV's strategic expansion into the healthcare and life sciences sector.
About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in
About Yike Regenerative Medicine
Jiangsu Yike Regenerative Medicine ( http://jsyk.club) is a high-tech enterprise specializing in regenerative medicine and precision anti-aging technologies. The company operates across multiple platforms, including genetic engineering, stem cell research, and immune cell applications. Yike co-established the Institute of Aging and Regenerative Medicine with
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the
Contacts:
Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings
View original content:SOURCE Visionary Holdings
FAQ
What did Visionary Holdings (GV) announce on October 22, 2025?
How much ownership will GV hold in the new joint venture (GV)?
Where will the Visionary Yike Stemcell Technologies headquarters likely be located?
What therapeutic areas will the GV joint venture initially target?
What development steps are required before commercialization by GV (GV)?
Is the diabetes evidence for Yike's technology clinical or preclinical?
